AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. The company's primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis. It also developed Skyrizi ($5 billion in 2022 revenues), an interleukin-23 (IL-23) inhibitor also used to treat autoimmune diseases. Its other major products include Botox ($5 billion in 2022 revenues), Imbruvica to treat cancer ($4.5 billion in 2022 revenues), Rinvoq to treat arthritis ($2.5 billion in 2022 revenues), Venclexta to treat leukemia and lymphoma ($2 billion in annual revenues), Vraylar to treat schizophrenia and bipolar disorder ($2 billion in 2022 revenues), and Mavyret to treat Hepatitis C ($1.5 billion in 2022 revenues). The company is also committed to product development for other treatments of cancer, neurologic diseases, eye care, and cystic fibrosis. More information...
According to PR-model, abbvie.com is ranked 72,102nd in multilingual Wikipedia, in particular this website is ranked 53,493rd in English Wikipedia.
The website is placed before parco.co.jp and after baftascotland.co.uk in the BestRef global ranking of the most important sources of Wikipedia.